Tight Glycemic Control in a Patient With Dementia and CKD
Mr. L is 79 years old with type 2 diabetes for 18 years, mild-moderate Alzheimer disease (MMSE 20/30), stage 3b CKD (eGFR 38 mL/min/1.73 m2), and a prior hypoglycemic seizure two years ago. His current regimen is glipizide 10 mg twice daily, metformin 1000 mg twice daily, and basal insulin 20 units at bedtime. His A1c is 6.9%. His daughter reports two episodes in the past month of confusion and sweating that resolved after orange juice. He has lost 4 kg unintentionally and has had two falls. He lives with his daughter, who manages his medications.
1. Evaluate whether his current A1c target and regimen are appropriate. What changes do you recommend and why?
Read the worked answer
An A1c of 6.9% is too aggressive for a 79-year-old with dementia, CKD 3b, prior severe hypoglycemia, weight loss, and falls. Guidelines for older adults with complex health and limited life expectancy target A1c roughly 8.0-8.5% and emphasize avoiding hypoglycemia over tight control. His regimen has several red flags. Glipizide is a sulfonylurea with long duration and high hypoglycemia risk, especially with CKD and erratic intake; it should be stopped or replaced. Metformin at 2000 mg/day exceeds recommended dosing in eGFR 30-44 (max about 1000 mg/day) and carries lactic acidosis risk with any acute illness; reduce to 500 mg twice daily or stop if eGFR falls below 30. Basal insulin 20 units is reasonable but should be titrated to fasting glucose 100-150 mg/dL rather than lower. The confusion and sweating episodes are likely hypoglycemia; the daughter should be taught to check glucose and use 15 g fast carbohydrate. Recommend deprescribing glipizide first, reducing metformin, and loosening the target to 8.0-8.5%. Recheck A1c in 3 months and review weight and falls.
2. His daughter asks whether his diabetes medicines could be simplified. Propose a regimen and monitoring plan that fits his cognition and kidney function.
Read the worked answer
Prioritize simplicity, low hypoglycemia risk, and renal safety. A reasonable regimen: stop glipizide; reduce metformin to 500 mg twice daily with meals (or once daily if eGFR drops); continue basal insulin but consider a lower starting dose (10-15 units) with titration by fasting glucose. If more coverage is needed, a DPP-4 inhibitor such as linagliptin requires no renal adjustment and has low hypoglycemia risk; sitagliptin and saxagliptin need dose reduction in CKD. Avoid SGLT2 inhibitors if he has volume depletion or recurrent genital infections, though they have renal benefits in selected patients. Monitoring: fasting glucose 2-3 times weekly and whenever he seems confused; A1c every 3 months; renal function every 3-6 months; weight and falls at each visit. Use a pill organizer and a single pharmacy. Teach the daughter sick-day rules: hold metformin during vomiting or dehydration. Set a shared goal of avoiding lows rather than achieving a specific number, and document the relaxed target in the chart.